US 12,467,095 B2
Salivary biomarkers of brain injury
Antonio Belli, East Wellow (GB); and Valentina Di Pietro, Birmingham (GB)
Assigned to THE UNIVERSITY OF BIRMINGHAM, Birmingham (GB)
Filed by THE UNIVERSITY OF BIRMINGHAM, Birmingham (GB)
Filed on Jul. 28, 2022, as Appl. No. 17/876,472.
Application 16/732,254 is a division of application No. 15/852,128, filed on Dec. 22, 2017, granted, now 10,563,262, issued on Feb. 18, 2020.
Application 17/876,472 is a continuation of application No. 16/732,254, filed on Dec. 31, 2019, granted, now 11,414,705.
Application 15/852,128 is a continuation in part of application No. PCT/GB2017/050231, filed on Jan. 30, 2017.
Claims priority of application No. 1603967 (GB), filed on Mar. 8, 2016.
Prior Publication US 2023/0295726 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01); C12Q 1/68 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method of diagnosing and treating mild traumatic brain injury (mTBI) in a human subject in need thereof, wherein the subject in need is one who has received an injury to the head, the method comprising:
detecting an amount of at least one miRNA in a saliva sample obtained from the subject, wherein the at least one miRNA comprises: (i) any combination of two miRNAs selected from the group consisting of miR-27b-3p, let-7i-5p, miR-142-3p, miR-107, and miR-135b-5p; (ii) any combination of three miRNAs selected from the group consisting of miR-27b-3p, let-7i-5p, miR-142-3p, miR-107, and miR-135b-5p; or (iii) any combination of four miRNA's selected from the group consisting of miR-27b-3p, let-7i-5p, miR-142-3p, miR-1072 and miR-135b-5p, wherein the detecting an amount of the at least one miRNA is performed using at least one of the following detection methods comprising: qPCR, miRNA assays, next-generation sequencing (NGS), microarrays, in-situ hybridization, and multiplex miRNA profiling assays;
identifying the subject as suffering from mTBI where the amount of the at least one miRNA is increased relative to a predetermined threshold value or relative to the amount of the miRNA in a control sample; and treating the subject identified as suffering from mTBI by administering to the subject one or more neuroprotective therapies.